Sanofi opens new $800m Tuas plant to produce biopharma products

It will hire 200 people by 2026 in roles such as engineering, data analysis and tech

- Timothy Goh

A French pharmaceutical giant has opened a new $800 million manufacturing facility in Tuas Biomedical Park.

The 58,000 sq m plant - Sanofi's second factory in Singapore - will produce vaccines and other biopharmaceutical products such as enzymes and laboratory-grown antibodies.

The new facility, called Modulus, will be fully operational by mid-2026. It will hire 200 people by 2026 in roles such as engineering, data analysis and tech.

Sanofi said Modulus is the world's first "modular concept" facility. The plant can accommodate 34 production modules with interconnected equipment, allowing it to switch production between different vaccines and biopharmaceutical products within days.

Modulus site head Koh Liang Hong told The Straits Times on Nov 27 that Singapore was chosen for the new facility due to the country's advanced manufacturing ecosystem, which supports the growth, innovation and sustainability goals of biopharmaceutical companies.